Contact Information: Contact: digiMedical Solutions, Inc. Investor Relations 214-722-3029 ir@digimedical.com www.digimedical.com
digiMedical Solutions, Inc. Announces Sales Channel Agreement With 1,500 Offices Nationwide
Company Releases Letter to Shareholders Discussing Progress Year-to-Date
| Source: digiMedical Solutions, Inc.
COLLEYVILLE, TX--(Marketwire - June 15, 2009) - digiMedical Solutions, Inc.™
(PINKSHEETS : DGMS ), today released a letter to shareholders from Company
CEO David Lee. The letter provides an operational update on the Company's
proprietary digital prescription software suite and increased sales
channels. The letter is included in its entirety below.
Separately, the Company recently launched a new interactive digital
prescription website allowing doctors and pharmacists to sign up online to
use digiMedical's products. The new site, www.digiReAuth.com, is part of an
ongoing effort by the Company to market digiRX, a thin client suite of
products providing digital prescription and reauthorization services to
doctors, pharmacists and patients. Utilizing the latest Microsoft
technologies such as .NET, AJAX and Microsoft SQL, the Company has
developed a suite of products to digitally manage the prescription
process. The Company's products comply with all HIPAA and DEA requirements
for patient medical record security.
Dear Fellow Shareholders,
In my shareholder letter released March 24th of this year, I outlined what
directions digiMedical would be undertaking for 2009. Let me recap these
directions for you and give you an update as to our progress.
Quarter One Activity
In recent months, the Company announced that it is growing its advisory
board, with the most recent addition being Jason Whisenant,
www.digiMedical.com/News/News.aspx. He and others like him will help expand
the Company's ability to forecast future trends and marketing segments in
the digital prescription industry, while at the same time improving our
sales and marketing division.
Over the course of the first quarter, the Company also launched our new
corporate website www.digiMedical.com, detailing our proprietary digital
prescription software. We also launched two other vital websites
www.digiRX.com and www.digiReAuth.com. These websites allow doctors and
pharmacists to find out about our products and services and sign up via the
Web. These websites leverage our software and significantly expand our
ability to sell to and service the market with minimal backend manpower,
resulting in a strong platform allowing for exponential sales growth.
Quarter Two Activity
Board member Philip Verges, CEO of NewMarket Technology (PINKSHEETS : NMKT ),
introduced VirtualHealth (OTCBB : VHGI ) and our Company. VirtualHealth has a
medical practice management system software product with a large client
base (for more information visit http://www.mosonline.com). I am pleased to
announce a new, signed contract with VirtualHealth to offer our software
and services in conjunction with their software to their client base of
over 1,500 offices nationwide.
This is a significant move for digiMedical to increase our sales channels
and our software's visibility in the market. In the third quarter, we will
contiue to work on this new sales channel to sign on more doctors. We plan
to issue more information on this agreement in the future and we will
continue to look for other large sales channels to partner with.
Additionally, in quarter three, we are planning to roll out a new version,
3.0, of our digiRX product.
Summary
digiMedical is focused on expanding our market share through reselling our
software products digiRX, digiReAuth and digiPRN Pharmacies by forging
agreements with partners that have an existing client base and sales
channels, like with VirtualHealth, that will significanlty increase our
sales and visibility in the market.
We recognize this is a difficult economy, and therefore perhaps a difficult
time to be a development stage company. However, we are enthusiastic about
our progress to date and consider our recent channel agreement, in
conjunction with our already proven, in production software to be a
significant milestone for the Company. I hope shareholders share our
enthusiasm and if so, I would ask you spread the word. Everyone knows at
least one doctor, so let them know about our products. We are proud of the
products we have developed and the security and savings they have brought
our clients. digiMedical is a great story, and we have set the foundations
for a bright future.
Thank you all for your patience and support.
Best regards,
David W. Lee
CEO of digiMedical Solutions, Inc.
To be added to digiMedical's corporate e-mail list to receive company
updates, please send an e-mail to ir@digimedical.com.
About digiMedical Solutions, Inc.™ (www.digiMedical.com)
digiMedical Solutions, Inc.™ is a pharmacy and medical technology
company focused on developing next generation, digital medical technology
with an emphasis on digital prescriptions (d-Prescriptions) that closely
align the doctor, pharmacist and patient. The company's planned growth will
come from three channels: direct marketing of the company's wireless based
d-prescription technology to physicians, direct marketing of the company's
digital call center services for refills and reauthorization and partnering
with independent pharmacy chains to focus sales with the technology suite.
Forward-Looking Statement
Statements included in this press release which are not historical in
nature, are intended to be, and are hereby identified as "Forward-Looking
Statements" for purposes of safe harbor provided by Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-Looking Statements may
be identified by words including "anticipate," "await," "envision,"
"foresee," "aim at," "believe," "intends," "estimates" including without
limitation, those relating to the company's future business prospects, are
subject to certain risks and uncertainties that could cause actual results
to differ materially from those indicated in the Forward-Looking
Statements. Readers are directed to the company's filings with the U.S.
Securities and Exchange Commission.